Related references
Note: Only part of the references are listed.Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
L. Kazianka et al.
LEUKEMIA (2017)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Jennifer R. Brown et al.
HAEMATOLOGICA (2017)
HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY
J.F. Seymour et al.
HEMATOLOGICAL ONCOLOGY (2017)
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
J. J. Shatzel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Jennifer R. Brown et al.
HAEMATOLOGICA (2017)
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials
Seongseok Yun et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A. Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Francois Caron et al.
BLOOD ADVANCES (2017)
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Steven E. Coutre et al.
CLINICAL CANCER RESEARCH (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia
M. A. Alberelli et al.
THROMBOSIS RESEARCH (2016)
Ibrutinib Inhibits Platelet Integrin a αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen
Alexander P. Bye et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Tec regulates platelet activation by GPVI in the absence of Btk
BT Atkinson et al.
BLOOD (2003)
Share Paper
